These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy. Basar OY; Mohammed S; Qoronfleh MW; Acar A Front Cell Dev Biol; 2024; 12():1369597. PubMed ID: 38813084 [TBL] [Abstract][Full Text] [Related]
3. Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. Ilari A; Cogliati V; Sherif N; Grassilli E; Ramazzotti D; Cordani N; Cazzaniga G; Di Bella C; Lavitrano M; Cazzaniga ME; Cerrito MG Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397874 [TBL] [Abstract][Full Text] [Related]
4. Case report: An exceptional responder of low-dose continuous 5-FU in a patient with Chan B; Lee JS; Yuan Y Front Oncol; 2023; 13():1305584. PubMed ID: 38288100 [TBL] [Abstract][Full Text] [Related]
5. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Alvarado-Miranda A; Lara-Medina FU; Muñoz-Montaño WR; Zinser-Sierra JW; Galeana PAC; Garza CV; Sanchez Benitez D; Limón Rodríguez JA; Arce Salinas CH; Guijosa A; Arrieta O Curr Oncol; 2023 Jun; 30(7):6097-6110. PubMed ID: 37504314 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer. Chai Y; Liu J; Jiang M; He M; Wang Z; Ma F; Wang J; Yuan P; Luo Y; Xu B; Li Q Thorac Cancer; 2023 Aug; 14(23):2259-2268. PubMed ID: 37402471 [TBL] [Abstract][Full Text] [Related]
7. Targeting Breast Cancer: An Overlook on Current Strategies. Iacopetta D; Ceramella J; Baldino N; Sinicropi MS; Catalano A Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835056 [TBL] [Abstract][Full Text] [Related]
13. Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration Scagliotti A; Capizzi L; Cazzaniga ME; Ilari A; De Giorgi M; Cordani N; Gallazzi M; Bruno A; Pelosi G; Albini A; Lavitrano M; Grassilli E; Cerrito MG Front Oncol; 2022; 12():998274. PubMed ID: 36531071 [TBL] [Abstract][Full Text] [Related]
14. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V; Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500 [TBL] [Abstract][Full Text] [Related]